Emerging therapies for chronic kidney disease: what is their role?
Authors:
- Eswari VilayurEVEswari Vilayur
- David C. H. HarrisDHDavid C. H. Harris
- 19 May 2009
- journal article
- review article
- Published by Springer Nature in Nature Reviews Nephrology
- Vol. 5 (7) , 375-383
Abstract
The prevalence of chronic kidney disease (CKD) is increasing worldwide. The best therapies currently available focus on the control of blood pressure and optimization of renin-angiotensin-aldosterone system blockade. Currently available agents are only partially effective against hard end points such as the development of end-stage renal disease and are not discussed in this Review. Many other agents have been shown to reduce proteinuria and delay progression in animal models of CKD. Some of these agents, including tranilast, sulodexide, thiazolidinediones, pentoxifylline, and inhibitors of advanced glycation end-products and protein kinase C, have been tested to a limited extent in humans. A small number of randomized controlled human trials of these agents have used surrogate markers such as proteinuria as end points rather than hard end points such as end-stage renal disease or doubling of serum creatinine level. Emerging therapies that specifically target and reverse pathological hallmarks of CKD such as inflammation, fibrosis and atrophy are needed to reduce the burden of this chronic disease and its associated morbidity. This Review examines the evidence for emerging pharmacological strategies for slowing the progression of CKD.Keywords
This publication has 80 references indexed in Scilit:
- Avosentan Reduces Albumin Excretion in Diabetics with MacroalbuminuriaJournal of the American Society of Nephrology, 2009
- Association of Oral Calcitriol with Improved Survival in Nondialyzed CKDJournal of the American Society of Nephrology, 2008
- Paricalcitol Reduces Albuminuria and Inflammation in Chronic Kidney DiseaseHypertension, 2008
- Oral Calcitriol for the Treatment of Persistent Proteinuria in Immunoglobulin A Nephropathy: An Uncontrolled TrialAmerican Journal of Kidney Diseases, 2008
- Sirolimus Reduces Polycystic Liver Volume in ADPKD PatientsJournal of the American Society of Nephrology, 2008
- Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trialsBMJ, 2008
- Shigatoxin-Induced Endothelin-1 Expression in Cultured Podocytes Autocrinally Mediates Actin RemodelingThe American Journal of Pathology, 2006
- Correction of Anemia with Epoetin Alfa in Chronic Kidney DiseaseNew England Journal of Medicine, 2006
- Antiproteinuric effect of oral paricalcitol in chronic kidney diseaseKidney International, 2005
- Reversal of Anemia by Erythropoietin Therapy Retards the Progression of Chronic Renal Failure, Especially in Nondiabetic PatientsNephron, 1997